Long-term suppression of neurodegeneration in chronic experimental optic neuritis: Antioxidant gene therapy

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 12, 2007, Pages 5360-5370

  Qi, Xiaoping ^a   Sun, Liang ^a   Lewin, Alfred S ^a   Hauswirth, William W ^a   Guy, John ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CATALASE; GADOLINIUM PENTETATE; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; SUPEROXIDE DISMUTASE; SOD3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LOSS; COMPUTER ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEMYELINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; INOCULATION; MOLECULAR CLONING; MOUSE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OPTIC NEURITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; SENSITIZATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VISUAL IMPAIRMENT; WESTERN BLOTTING; ADENO ASSOCIATED VIRUS; ANIMAL; ATROPHY; CELL CULTURE; CHRONIC DISEASE; DBA MOUSE; DEGENERATIVE DISEASE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOELECTRON MICROSCOPY; INJECTION; METABOLISM; MYELIN SHEATH; PATHOLOGY; PHYSIOLOGY; RAT;

ANIMALS; ANTIOXIDANTS; ATROPHY; AXONS; BLOTTING, WESTERN; CATALASE; CELLS, CULTURED; CHRONIC DISEASE; DEPENDOVIRUS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; GENETIC VECTORS; INJECTIONS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED DBA; MICROSCOPY, IMMUNOELECTRON; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; OPTIC NERVE; OPTIC NEURITIS; RATS; RETINAL GANGLION CELLS; SUPEROXIDE DISMUTASE;

EID: 38549125007     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0254     Document Type: Article

References (61)

1. Alvord EC Jr. The challenge: how good a model of MS is EAE today? Prog Clin Biol Res. 1984;146:3-5.
2. Baker D, Hankey DJ. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther. 2003;10:844-853.
3. Pedotti R, De Voss JJ, Steinman L, et al. Involvement of both "allergic" and "autoimmune" mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol. 2003;24:479-484.
4. Lisak RP, Zweiman B, Blanchard N, et al. Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci. 1983;62:281-293.
5. Renno T, Taupin V, Bourbonniere L, et al. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci. 1998;12:376-389.
6. Bach JF. Cytokine-based immunomodulation of autoimmune diseases: an overview. Transplant Proc. 1996;28:3023-3025.
7. Bettelli E, Nicholson LB. The role of cytokines in experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz). 2000;48:389-398.
8. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol. 2000;47:127-131.
9. Duong TT, Finkelman FD, Singh B, et al. Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J Neuroimmunol. 1994;53:101-107.
10. Floris S, Ruuls SR, Wierinckx A, et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol. 2002;127:69-79.
11. Martin R. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. J Neural Transm Suppl. 1997;49:53-67.
12. Ruuls SR, de Labie MC, Weber KS, et al. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J Immunol. 1996;157:5721-5731.
13. Schmidt J, Sturzebecher S, Toyka KV, et al. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res. 2001;65:59-67.
14. van der Meide PH, de Labie MC, Ruuls SR, et al. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats: rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol. 1998;84:14-23.
15. Wender M, Michalak S, Wygladalska-Jernas H. The effect of short-term treatment with interferon beta 1a on acute experimental allergic encephalomyelitis. Folia Neuropathol. 2001;39:91-93.
16. Yu M, Nishiyama A, Trapp BD, et al. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol. 1996;64:91-100.
17. Hu P, Pollard J, Hunt N, et al. Microvascular and cellular responses in the optic nerve of rats with acute experimental allergic encephalomyelitis (EAE). Brain Pathol. 1998;8:475-486.
18. Guy J, Fitzsimmons J, Ellis EA, et al. Intraorbital optic nerve and experimental optic neuritis: correlation of fat suppression magnetic resonance imaging and electron microscopy. Ophthalmology. 1992;99:720-725.
19. Guy J, Ellis EA, Rao NA. Hydrogen peroxide localization in experimental optic neuritis. Arch Ophthalmol. 1990;108:1614-1621.
20. Guy J, Fitzsimmons J, Ellis EA, et al. Gadolinium-DTPA-enhanced magnetic resonance imaging in experimental optic neuritis. Ophthalmology. 1990;97:601-607.
21. Honegger CG, Krenger W, Langemann H. Ree radical scavengers in experimental autoimmune encephalomyelitis. Schweiz Arch Neurol Psychiatr. 1989;140:25-27.
22. Cowden WB, Cullen FA, Staykova MA, et al. Nitric oxide is a potential down-regulating molecule in autoimmune disease: inhibition of nitric oxide production renders PVG rats highly susceptible to EAE. J Neuroimmunol. 1998;88:1-8.
23. Ruuls SR, Van Der LS, Sontrop K, et al. Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. Clin Exp Immunol. 1996;103:467-474.
24. Mohamed A, Shoker A, Bendjelloul F, et al. Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone: an oxidative stress inhibitor. Biomed Sci Instrum. 2003;39:440-445.
25. Mohamed AA, Avila JG, Schultke E, et al. Amelioration of experimental allergic encephalitis (EAE) through phase 2 enzyme induction. Biomed Sci Instrum. 2002;38:9-13.
26. Clancy CJ, Yu YC, Lewin A, et al. Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B. Antimicrob Agents Chemother. 1998;42:509-513.
27. Spitsin SV, Scott GS, Mikheeva T, et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med. 2002;33:1363-1371.
28. 2 toxicity. Proc Natl Acad Sci USA. 1992;89:9715-9719.
29. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Lab Invest. 1996;75:617-636.
30. Oury TD, Piantadosi CA, Crapo JD. Cold-induced brain edema in mice: involvement of extracellular superoxide dismutase and nitric oxide. J Biol Chem. 1993;268:15394-15398.
31. Sheng H, Bart RD, Oury TD, et al. Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. Neuroscience. 1999;88:185-191.
32. Guy J, Qi X, Hauswirth WW. Adenoassociated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc Natl Acad Sei USA. 1998;95:13847-13852.
33. Qi X, Hauswirth WW, Guy J. Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis. Mol Vis. 2007;13:1-11.
34. Hauswirth WW, Lewin AS, Zolotukhin S, et al. Production and purification of recombinant adenoassociated virus. Methods Enzymol. 2000;316:743-761.
35. Tsoi VL, Hill KE, Carlson NG, et al. Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol. 2006;26:87-94.
36. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis (Comment). Ann Neurol. 2004;56:308.
37. DeLuca GC, Williams K, Evangelou N, et al. The contribution of demyelination to axonal loss in multiple sclerosis. Brain. 2006;129:1507-1516.
38. Bjartmar C, Kinkel RP, Kidd G, et al. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology. 2001;57:1248-1252.
39. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183-198.
40. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59:963-969.
41. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58:383-391.
42. Aboul-Enein F, Weiser P, Hoftberger R, et al. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis. Acta Neuropathol (Berl). 2006;111:539-547.
43. Papadopoulos D, Pham-Dinh D, Reynolds R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol. 2006;197:373-385.
44. Lieven CJ, Hoegger MJ, Schlieve CR, et al. Retinal ganglion cell axotomy induces an increase in intracellular superoxide anion. Invest Ophthalmol Vis Sci. 2006;47:1477-1485.
45. 2 and extravasated serum albumin. Invest Ophthalmol Vis Sci. 1994;35:1114-1123.
46. Guy J, Ellis EA, Mames R, et al. Role of hydrogen peroxide in experimental optic neuritis: a serial quantitative ultrastructural study. Ophthalmic Res. 1993;25:253-264.
47. Sheng H, Brady TC, Pearlstein RD, et al. Extracellular superoxide dismutase deficiency worsens outcome from focal cerebral ischemia in the mouse. Neurosci Lett. 1999;267:13-16.
48. Qi X, Lewin AS, Sun L, et al. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2007;48:681-691.
49. Qi X, Lewin AS, Sun L, et al. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem. 2006;281:31950-31962.
50. Shriver LP, Dittel BN. T-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis. Am J Pathol. 2006;169:999-1011.
51. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis [see comments]. N Engl J Med. 1998;338:278-285.
52. Hickman SJ, Brierley CM, Brex PA, et al. Continuing optic nerve atrophy following optic neuritis: a serial MRI study. Mult Scler. 2002;8:339-342.
53. Hickman SJ, Kapoor R, Jones SJ, et al. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74:1139-1141.
54. Vedula S, Brodney-Folse S, Gal R, et al. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2007;CD001430.
55. Diem R, Hobom M, Maier K, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci. 2003;23:6993-7000.
56. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis Study Group [see comments]. N Engl J Med. 1992;326:581-588.
57. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514-1522.
58. Maier K, Kuhnert AV, Taheri N, et al. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol. 2006;169:1353-1364.
59. Diem R, Taheri N, Dietz GP, et al. HIV-Tat-mediated Bcl-XL delivery protects retinal ganglion cells during experimental autoimmune optic neuritis. Neurobiol Dis. 2005;20:218-226.
60. Banisor I, Kalman B. Bcl-2 and its homologues in the brain of patients with multiple sclerosis. Mult Scler. 2004;10:176-181.
61. Diem R, Sattler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain. 2005;128:375-385.